# US 8,277,847 B2 · Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,847 B2
- Document ID: US8277847B2
- Status: Granted
- Kind: B2
- Application number: 12/371,287
- Filed: 2009-02-13
- Published: 2009-06-18
- Granted: 2012-10-02
- Earliest claimed: 2001-08-14
- Assignees: Tel Aviv University Future Technology Development L.P.
- Inventors: Rimona Margalit; Dan Peer
- Web page: https://patentgrep.com/patent/US8277847B2

## CPC

- A61K 9/5036: {Polysaccharides, e.g. gums, alginate; Cyclodextrin}
- A61K 9/0043: {Nose}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 9/5192: {Processes}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/212: {IFN-alpha}
- A61K 38/28: Insulins
- A61K 38/385: {Serum albumin}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/544: {Phospholipids}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6927: {the form being a solid microparticle having no hollow or gas-filled cores}
- A61K 47/6939: {the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin}
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0091: {Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer}
- A61K 51/1251: {micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4725: {Proteoglycans, e.g. aggreccan}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.

## Claims

### Claim 1

A method for treating an animal suffering from a cancer, wherein the cancer cells have a glycosaminoglycan recognition site comprising administering to said animal an effective amount of an anticancer drug for treating said cancer encapsulated in a water-insoluble lipidated glycosaminoglycan particle in the form of a sphere with the glycosaminoglycan portion of the particle forming a shell on the outside and the lipid portion of the particle forming the inside, without the presence of liposome, said particle comprising the reaction product of at least one glycosaminoglycan with at least one lipid having a primary amino group, wherein the ratio of said at least one lipid having a primary amino group to said at least one glycosaminoglycan is in the range of 1:1 and 5:1 to 20:1 and said at least one glycosaminoglycan has a molecular weight within the range of about 1×105 to about 1×107 daltons.

### Claim 2 (depends on 1)

The method of claim 1, wherein said drug is administered orally, intravenously, intranasally or topically.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is a cancer of the central nervous system of an animal.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cancer of the central nervous system is a glioma.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is a metastatic cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein said water-soluble lipidated glycosaminoglycan particle is administered intraocularly, intramuscularly, or subcutaneously.

### Claim 7 (depends on 1)

The method of claim 1, wherein said at least one glycosaminoglycan is selected from the group consisting of hyaluronic acid, keratan sulfate, chondroitin sulfate, heparin sulfate, heparan sulfate, dermatin sulfate, salts, and mixtures thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein said at least one glycosaminoglycan is hyaluronic acid.

### Claim 9 (depends on 1)

The method of claim 1, wherein the particle size ranges from about 2-5 microns.

### Claim 10 (depends on 1)

The method of claim 1, wherein the particle size ranges from about 50-200 nanometers.

### Claim 11 (depends on 1)

The method of claim 1, wherein the ratio of said at least one lipid having a primary amino group to said at least one glycosaminoglycan is in the range of 5:1 to 20:1 w/w.

### Claim 12 (depends on 1)

The method of claim 1, wherein said at least one lipid having a primary amino group is a phosphatidylethanolamine.

### Claim 13 (depends on 1)

The method of claim 1, wherein the ratio of said at least one lipid having a primary amino group to said at least one glycosaminoglycan is in the range of 1:1 w/w.

### Claim 14

A method for targeted delivery of a biologically active material to a cell having a glycosaminoglycan recognition site, comprising administering a bioactive agent encapsulated in a water-insoluble lipidated glycosaminoglycan particle in the form of a sphere with the glycosaminoglycan portion of the particle forming a shell on the outside and the lipid portion of the particle forming the inside, without the presence of liposome, said particle comprising the reaction product of at least one glycosaminoglycan with at least one lipid having a primary amino group,
wherein:
the glycosaminoglycan in the glycosaminoglycan particle corresponds to the glycosaminoglycan recognition site on the cell to which the biologically active material is to be delivered;
the ratio of said at least one lipid having a primary amino group to said at least one glycosaminoglycan is in the range of 1:1 and 5:1 to 20:1; and
said at least one glycosaminoglycan has a molecular weight within the range of about 1×105 to about 1×107 daltons.

### Claim 15 (depends on 14)

The method of claim 14, wherein said at least one glycosaminoglycan is selected from the group consisting of hyaluronic acid, keratan sulfate, chondroitin sulfate, heparin sulfate, heparan sulfate, dermatin sulfate, salts, and mixtures thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein said at least one glycosaminoglycan is hyaluronic acid.

### Claim 17 (depends on 14)

The method of claim 14, wherein said at least one lipid having a primary amino group is a phosphatidyl ethanolamine.

### Claim 18 (depends on 14)

The method of claim 14, wherein the ratio of said at least one lipid having a primary amino group to said at least one glycosaminoglycan is in the range of 5:1 to 20:1 w/w.

### Claim 19 (depends on 14)

The method of claim 14, wherein the ratio of said at least one lipid having a primary amino group to said at least one glycosaminoglycan is in the range of 1:1 w/w.

### Claim 20 (depends on 14)

The method of claim 14, wherein the particle size ranges from about 2-5 microns.

### Claim 21 (depends on 14)

The method of claim 14, wherein the particle size ranges from about 50-200 nanometers.

### Claim 22 (depends on 1)

The method of claim 1, wherein the anticancer drug is mitomycin C.

### Claim 23 (depends on 1)

The method of claim 1, wherein the anticancer drug is doxorubicin.

### Claim 24 (depends on 1)

The method of claim 1, wherein the anticancer drug is vinblastine.
